BOSTON--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for ...

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two ...

(NASDAQ: CRDL) recently received FDA Orphan Drug Designation for CardiolRx™ in treating pericarditis, with a robust MAVERIC ...

A decline in Michigan's overdose deaths is marking progress in the state's ongoing battle against opioids, according to the ...